<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ut m_source= Chrome&amp;v=2.17.9.post6+86293ac&amp;ff=20230710063622&amp;utm_medium=rss&amp;utm_campaign=pubmed- 2&amp;fc=20230708114047<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;ff=20230710063622&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;fc=20230708114047" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 7 月 10 日星期一 10:36:24 +0000</lastbuilddate><pubDate> Sat, 08 Jul 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>开发用于突触核蛋白病成像的 α-突触核蛋白正电子发射断层扫描示踪剂</title><link/>https://pubmed.ncbi.nlm.nih.gov/37421950/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230710063622&amp;v=2.17.9.post6+86293ac<description>突触核蛋白病的特征是 α-突触核蛋白 (α-Syn) 在大脑中聚集。突触核蛋白病的正电子发射断层扫描 (PET) 成像需要选择性结合 α-Syn 沉积物的放射性药物。PET 示踪剂 [^(18)F]-F0502B ，它显示出对 α-Syn 的高结合亲和力，但对 Aβ 或 Tau 原纤维没有高结合亲和力，并且优先结合大脑切片中的 α-Syn 聚集体。采用几个循环... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 6 月 27 日：S0092-8674(23)00644-X. doi: 10.1016/j.cell.2023.06.004. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">突触核蛋白病的特点是大脑中 α-突触核蛋白 (α-Syn) 聚集体的积累。突触核蛋白病的正电子发射断层扫描 (PET) 成像需要选择性结合 α-Syn 沉积物的放射性药物。PET 示踪剂 [ <sup>18</sup> F]-F0502B，显示对 α-Syn 具有高结合亲和力，但对 Aβ 或 Tau 原纤维没有高结合亲和力，并且优先与脑切片中的 α-Syn 聚集体结合。对来自多个体外原纤维、神经元内聚集体和神经退行性疾病脑切片进行多个循环的反筛选小鼠模型和人类受试者，[ <sup>18</sup> F]-F0502B 对小鼠和非人类灵长类 PD 模型大脑中的 α-Syn 沉积物进行成像。-Syn 原纤维-F0502B 复合物通过冷冻电镜显示，并揭示了 F0502B 在原纤维上的平行对角堆叠因此，[ <sup>18</sup> F]-F0502B 是一种有前途的先导化合物，用于对突触核蛋白病中聚集的 α-Syn 进行成像。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37421950/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37421950</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.06.004>10.1016/j.cell.2023.06.004</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37421950</guid><pubDate> Sat, 08 Jul 2023 06:00:00 -0400</pubDate><dc:creator>杰翔</dc:creator><dc:creator>陶友奇</dc:creator><dc:creator>夏一元</dc:creator><dc:creator>罗士林</dc:creator><dc:creator>赵勤越</dc:creator><dc:creator>李博伟</dc:creator><dc:creator>张小倩</dc:creator><dc:creator>孙云鹏</dc:creator><dc:creator>夏文成</dc:creator><dc:creator>张明明更多</dc:creator><dc:creator>成洙康</dc:creator><dc:creator>安恩熙</dc:creator><dc:creator>刘霞</dc:creator><dc:creator>谢方</dc:creator><dc:creator>关益辉</dc:creator><dc:creator>杨珍妮</dc:creator><dc:creator>卜立宏</dc:creator><dc:creator>吴胜熙</dc:creator><dc:creator>王晓川</dc:creator><dc:creator>曹学兵更多</dc:creator><dc:creator>刘丛</dc:creator><dc:creator>张振涛</dc:creator><dc:creator>李丹</dc:creator><dc:creator>叶克强</dc:creator><dc:date>2023-07-08</dc:date><dc:source>细胞</dc:source><dc:title>开发用于突触核蛋白病成像的 α-突触核蛋白正电子发射断层扫描示踪剂</dc:title><dc:identifier>下午：37421950</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.004</dc:identifier></item><item><title> TMEM106B 是介导不依赖 ACE2 的 SARS-CoV-2 细胞进入的受体</title><link/>https://pubmed.ncbi.nlm.nih.gov/37421949/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230710063622&amp;v=2.17.9.post6+86293ac<description> SARS-CoV-2 与广泛的组织向性相关，这一特征通常由宿主细胞上进入受体的可用性决定。在这里，我们证明 TMEM106B（一种溶酶体跨膜蛋白）可以作为 SARS-CoV-2 的替代受体进入血管紧张素转换酶 2 (ACE2) 阴性细胞。刺突取代 E484D 增加 TMEM106B 结合，从而增强 TMEM106B 介导的进入。TMEM106B 特异性单克隆抗体可阻断 SARS-CoV-2 感染，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 7 月 3 日：S0092-8674(23)00645-1.doi: 10.1016/j.cell.2023.06.005.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> SARS-CoV-2 与广泛的组织向性相关，这一特征通常由宿主细胞上进入受体的可用性决定。在这里，我们证明 TMEM106B（一种溶酶体跨膜蛋白）可以作为 SARS-CoV-2 的替代受体进入血管紧张素转换酶 2 (ACE2) 阴性细胞。刺突取代 E484D 增加 TMEM106B 结合，从而增强 TMEM106B 介导的进入。TMEM106B 特异性单克隆抗体阻断 SARS-CoV-2 感染，证明 TMEM106B 在病毒进入中的作用。使用 X 射线晶体学、低温电子显微镜 (cryo-EM) 和氢氘交换质谱 (HDX-MS)，我们表明 TMEM106B 的管腔结构域 (LD) 与 SARS-CoV-的受体结合基序接合。 2 刺突。最后，我们表明 TMEM106B 促进刺突介导的合胞体形成，表明 TMEM106B 在病毒融合中的作用。总之，我们的研究结果确定了一种不依赖于 ACE2 的 SARS-CoV-2 感染机制，该机制涉及与受体硫酸乙酰肝素的协同相互作用和 TMEM106B。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37421949/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37421949</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.06.005>10.1016/j.cell.2023.06.005</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37421949</guid><pubDate> Sat, 08 Jul 2023 06:00:00 -0400</pubDate><dc:creator>吉姆·巴根</dc:creator><dc:creator>马丁·雅克敏</dc:creator><dc:creator>伦特耶人</dc:creator><dc:creator>埃尔斯·范斯特雷尔斯</dc:creator><dc:creator>瓦莱丽·派伊</dc:creator><dc:creator>安东尼·G·沃贝尔</dc:creator><dc:creator>瓦莱里娅·卡尔瓦雷西</dc:creator><dc:creator>斯蒂芬·R·马丁</dc:creator><dc:creator>克洛伊·鲁斯坦</dc:creator><dc:creator>诺拉·B·克罗宁</dc:creator><dc:creator>埃蒙·雷丁</dc:creator><dc:creator>亨德里克·扬·蒂博</dc:creator><dc:creator>托马斯·维克鲁斯</dc:creator><dc:creator>皮特·梅斯</dc:creator><dc:creator>弗雷德里克·德·斯梅特</dc:creator><dc:creator>Angie Yee更多</dc:creator><dc:creator>托伊·尼维查永</dc:creator><dc:creator>玛丽娜·罗尔</dc:creator><dc:creator>娜塔莉亚·佛朗哥-埃尔南德斯</dc:creator><dc:creator>埃尔维·莱恩</dc:creator><dc:creator>阿卢莎·安德烈·马姆查克</dc:creator><dc:creator>马克西姆·阿·杨-查蓬</dc:creator><dc:creator>——埃里克·布朗</dc:creator><dc:creator>彼得·切列帕诺夫</dc:creator><dc:creator>德克·戴勒曼斯</dc:creator><dc:date>2023-07-08</dc:date><dc:source>细胞</dc:source><dc:title>TMEM106B 是介导不依赖 ACE2 的 SARS-CoV-2 细胞进入的受体</dc:title><dc:identifier>下午：37421949</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.005</dc:identifier></item><item><title>有效膜张力：细胞动力学的远程积分器</title><link/>https://pubmed.ncbi.nlm.nih.gov/37419084/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230710063622&amp;v=2.17.9.post6+86293ac<description>膜张力已被提议以机械方式耦合沿细胞边界的过程。在本期《细胞》中，De Belly 等人表明，局部突出或收缩会在几秒钟内引起全局膜张力增加，而仅涉及膜的张力扰动仍然是局部的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 2023 年 7 月 6 日；186(14):2956-2958.doi <b>：</b> 10.1016/j.cell.2023.05.033。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">膜张力已被提议以机械方式耦合沿细胞边界的过程。在本期《细胞》中，De Belly 等人表明，局部突出或收缩会在几秒钟内引起全局膜张力增加，而仅涉及膜的张力扰动仍然是局部的。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37419084/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37419084</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.05.033>10.1016/j.cell.2023.05.033</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37419084</guid><pubDate> Fri, 07 Jul 2023 06:00:00 -0400</pubDate><dc:creator>基内雷·凯伦</dc:creator><dc:date>2023-07-07</dc:date><dc:source>细胞</dc:source><dc:title>有效膜张力：细胞动力学的远程积分器</dc:title><dc:identifier>下午：37419084</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.05.033</dc:identifier></item><item><title>科学总监：学术领导力的典范</title><link/>https://pubmed.ncbi.nlm.nih.gov/37419083/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230710063622&amp;v=2.17.9.post6+86293ac<description>当前的学术领导模式对拥有高度活跃研究项目的科学家提出了独特的要求。具有专门科学主任的免费模式可以消除这种压力，并允许通过合作伙伴关系对社区进行更大的机构投资。这种模式。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 2023 年 7 月 6 日；186(14):2951-2955.doi <b>：</b> 10.1016/j.cell.2023.05.036。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">当前的学术领导模式对拥有高度活跃研究项目的科学家提出了独特的要求。具有专门科学主任的免费模式可以消除这种压力，并允许通过合作伙伴关系对社区进行更大的机构投资。这种模式。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37419083/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37419083</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.05.036>10.1016/j.cell.2023.05.036</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37419083</guid><pubDate> Fri, 07 Jul 2023 06:00:00 -0400</pubDate><dc:creator>卡罗琳·亨德利</dc:creator><dc:creator>安东尼奥·J·吉拉尔德斯</dc:creator><dc:date>2023-07-07</dc:date><dc:source>细胞</dc:source><dc:title>科学总监：学术领导力的典范</dc:title><dc:identifier>下午：37419083</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.05.036</dc:identifier></item><item><title>关注缺血性心脏病：从机制到防治</title><link/>https://pubmed.ncbi.nlm.nih.gov/37418309/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230710063622&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 《欧洲心脏杂志》2023 年 7 月 7 日；44(26):2351-2354.doi: 10.1093/eurheartj/ehad422。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37418309/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37418309</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad422>10.1093/eurheartj/ehad422</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37418309</guid><pubDate> Fri, 07 Jul 2023 06:00:00 -0400</pubDate><dc:creator>菲利波·克雷亚</dc:creator><dc:date>2023-07-07</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>关注缺血性心脏病：从机制到防治</dc:title><dc:identifier>下午：37418309</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad422</dc:identifier></item><item><title>冠状动脉旁路移植术后移植失败及其与患者特征和临床事件的关联：影像学随访临床试验的个体患者数据汇总分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37417248/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230710063622&amp;v=2.17.9.post6+86293ac<description>结论：在当代实践中，接受 CABG 的患者中移植失败仍然很常见，并且与不良心脏事件密切相关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 7 月 7 日。doi：10.1161/CIRCULATIONAHA.123.064090。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：移植物通畅是冠状动脉旁路移植术 (CABG) 获益的假定机制，介于移植物失败和 CABG 后临床事件之间。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们汇集了来自随机临床试验的个体患者数据，并进行了系统的 CABG 移植物成像，以评估移植物失败的发生率及其与临床危险因素的关联。主要结果是 CABG 后和成像前发生的心肌梗死或重复血运重建的复合结果。采用两阶段荟萃分析方法来评估移植失败与主要结局之间的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：纳入 7 项试验，包括 4413 名患者（平均年龄 64.4±9.1 岁；777 名女性 [17.6%]；3636 名男性 [82.4%]）和 13 163 个移植物（8740 个隐静脉移植物和 4423 个动脉移植物）。 1.02 年（Q1；Q3：1.00；1.03）。1487 名患者（33.7%）和 2190 名移植物（16.6%）发生移植失败。年龄（调整优势比 [aOR]，1.08 [每 10 年增量] [95 % CI，1.01-1.15]； <i>P</i> = 0.03）、女性（aOR，1.27 [95% CI，1.08-1.50]； <i>P</i> = 0.004）和吸烟（aOR，1.20 [95% CI，1.04-1.38]； <i>P</i> = 0.01）与移植失败独立相关，而他汀类药物则与保护作用相关（aOR，0.74 [95% CI，0.63-0.88]； <i>P</i> &lt;0.001）。CABG 和影像学评估之间发生的心肌梗死或重复血运重建（移植失败的患者为 8.0%，无移植失败的患者为 1.7%；aOR，3.98 [95% CI，3.54–4.47]； <i>P</i> &lt;0.001)。移植失败还与心肌梗死或重复血运重建的风险增加相关影像学检查后（7.8% 对比 2.0%；aOR，2.59 [95% CI，1.86–3.62]； <i>P</i> &lt;0.001）。与没有移植失败的患者相比，移植失败的患者（11.0% 对比 2.1%；aOR，2.79 [95% CI] ，2.01-3.89]； <i>P</i> &lt;0.001）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在当代实践中，接受 CABG 的患者中移植失败仍然很常见，并且与不良心脏事件密切相关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37417248/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37417248</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064090>10.1161/CIRCULATIONAHA.123.064090</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37417248</guid><pubDate> Fri, 07 Jul 2023 06:00:00 -0400</pubDate><dc:creator>马里奥·高迪诺</dc:creator><dc:creator>西格丽德·桑德纳</dc:creator><dc:creator>凯文·安</dc:creator><dc:creator>阿纳尔多·迪马利</dc:creator><dc:creator>安东尼诺·迪弗朗哥</dc:creator><dc:creator>卡蒂亚·奥迪西奥</dc:creator><dc:creator>拉米亚·哈里克</dc:creator><dc:creator>罗伯托·佩雷斯格罗瓦斯-奥拉里亚</dc:creator><dc:creator>乔瓦尼·索莱蒂</dc:creator><dc:creator>斯蒂芬·E·弗雷姆斯</dc:creator><dc:creator>大卫·L·黑尔</dc:creator><dc:creator>亚历山大·库里克</dc:creator><dc:creator>安德烈·拉米</dc:creator><dc:creator>乔伊斯·佩珀</dc:creator><dc:creator>——马克·鲁尔</dc:creator><dc:creator>朱里恩·M·滕伯格</dc:creator><dc:creator>——劳拉·M·威廉森</dc:creator><dc:creator>赵强</dc:creator><dc:creator>丹尼尔·M·沃伊迪拉</dc:creator><dc:creator>迪帕克·巴特</dc:creator><dc:creator>约翰·H·亚历山大</dc:creator><dc:creator>比约恩·雷德福斯</dc:creator><dc:date>2023-07-07</dc:date><dc:source>循环</dc:source><dc:title>冠状动脉旁路移植术后移植失败及其与患者特征和临床事件的关联：影像学随访临床试验的个体患者数据汇总分析</dc:title><dc:identifier>下午：37417248</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064090</dc:identifier></item><item><title>确定全球健康的营养优先事项：是时候更加纯粹地关注保护性食品了</title><link/>https://pubmed.ncbi.nlm.nih.gov/37414412/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230710063622&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 6:ehad325.doi: 10.1093/eurheartj/ehad325. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37414412/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37414412</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad325>10.1093/eurheartj/ehad325</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37414412</guid><pubDate> Thu, 06 Jul 2023 06:00:00 -0400</pubDate><dc:creator>达里乌什·莫扎法里安</dc:creator><dc:date>2023-07-06</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>确定全球健康的营养优先事项：是时候更加纯粹地关注保护性食品了</dc:title><dc:identifier>下午：37414412</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad325</dc:identifier></item><item><title> 80 个国家的饮食、心血管疾病和死亡率</title><link/>https://pubmed.ncbi.nlm.nih.gov/37414411/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230710063622&amp;v=2.17.9.post6+86293ac<description>结论：在世界所有地区，含有较多水果、蔬菜、坚果、豆类、鱼类和全脂乳制品的饮食与较低的 CVD 和死亡率相关，特别是在这些食物消费量较低的收入较低的国家。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 6:ehad269.doi: 10.1093/eurheartj/ehad269. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目标：利用前瞻性城乡流行病学 (PURE) 研究的数据，制定与健康结果相关且在全球适用的健康饮食评分，并将其复制到五项独立研究中，对象为来自 80 个国家的总共 245 000 人。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法和结果：PURE 研究中对来自 21 个国家的 147 642 名普通人群进行了健康饮食评分，并在来自 70 个国家的五项大型独立研究中检验了评分与事件关联的一致性。饮食评分是根据六种食物制定的，每种食物都与显着降低的死亡风险相关[即水果、蔬菜、坚果、豆类、鱼类和乳制品（主要是全脂）；分数范围，0-6]主要结局指标是全因死亡率和主要心血管事件[心血管疾病（CVD）]。在PURE中位随访9.3年期间，与饮食评分≤1分的饮食评分相比，饮食评分≥5分的饮食评分积分与较低的死亡风险[风险比 (HR) 0.70；95% 置信区间 (CI) 0.63-0.77)]、CVD (HR 0.82；0.75-0.91)、心肌梗死 (HR 0.86；0.75-0.99) 风险相关) 和中风 (HR 0.81; 0.71-0.93). 0.72-0.87)、心肌梗死 (HR 0.85; 0.71-0.99)，以及非统计显着性较低的中风风险 (HR 0.87; 0.73-1.03)。首次心肌梗死 [比值比 (OR) 0.72; 0.65-0.80] 和中风 (OR 0.57; 0.50-0.65)。与国民生产总值较高的地区相比，较高的饮食评分与死亡或 CVD 风险显着降低相关。收入（异质性 P&lt;0.0001）。PURE 评分显示与死亡或 CVD 的关联性比其他几种常见饮食评分稍强（每次比较 P&lt;0.001）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在世界所有地区，含有较多水果、蔬菜、坚果、豆类、鱼类和全脂乳制品的饮食与较低的 CVD 和死亡率相关，特别是在这些食物消费量较低的收入较低的国家。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37414411/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37414411</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad269>10.1093/eurheartj/ehad269</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37414411</guid><pubDate> Thu, 06 Jul 2023 06:00:00 -0400</pubDate><dc:creator>安德鲁·门特</dc:creator><dc:creator>马赫希德·德赫甘</dc:creator><dc:creator>苏马西·兰加拉詹</dc:creator><dc:creator>马丁·奥唐纳</dc:creator><dc:creator>胡伟红</dc:creator><dc:creator>吉尔·达格奈</dc:creator><dc:creator>安德烈亚斯·维尔戈斯更多</dc:creator><dc:creator>斯科特·李尔</dc:creator><dc:creator>李伟</dc:creator><dc:creator>拉斐尔·迪亚兹更多</dc:creator><dc:creator>阿尔瓦罗·阿韦祖姆</dc:creator><dc:creator>帕特里西奥·洛佩兹-哈拉米洛</dc:creator><dc:creator>费尔南多·拉纳斯</dc:creator><dc:creator>苏马蒂·斯瓦米纳坦</dc:creator><dc:creator>曼米特·考尔</dc:creator><dc:creator>K Vijayakumar更多</dc:creator><dc:creator>维斯瓦纳坦·莫汉</dc:creator><dc:creator>拉吉夫·古普塔</dc:creator><dc:creator>安杰伊·苏巴</dc:creator><dc:creator>罗马娜·伊克巴尔</dc:creator><dc:creator>丽塔·优素福</dc:creator><dc:creator>努辛·穆罕默德迪法德</dc:creator><dc:creator>拉沙卡提</dc:creator><dc:creator>纳菲扎·马特·纳西尔</dc:creator><dc:creator>库比莱·卡西达格</dc:creator><dc:creator>安妮卡·罗森格伦</dc:creator><dc:creator>阿夫扎尔侯赛因·尤苏法利</dc:creator><dc:creator>雪绒花温策尔-维尔容</dc:creator><dc:creator>Jephat Chifamba更多</dc:creator><dc:creator>安东尼奥跳舞</dc:creator><dc:creator>哈立德·F·阿尔哈比卜</dc:creator><dc:creator>凯伦·叶茨</dc:creator><dc:creator>昆张</dc:creator><dc:creator>赫策尔·C·格斯坦</dc:creator><dc:creator>萨利姆·优素福</dc:creator><dc:date>2023-07-06</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>80 个国家的饮食、心血管疾病和死亡率</dc:title><dc:identifier>下午：37414411</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad269</dc:identifier></item><item><title>疫苗增强的 CAR T 与宿主免疫串扰，以排斥具有抗原异质性的肿瘤</title><link/>https://pubmed.ncbi.nlm.nih.gov/37413990/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230710063622&amp;v=2.17.9.post6+86293ac<description>嵌合抗原受体（CAR）T细胞疗法可以有效治疗人类癌症，但CAR识别的抗原的丢失构成了主要障碍。我们发现体内CAR T细胞疫苗加强会触发内源性免疫系统的参与来规避抗原阴性肿瘤逃逸。疫苗增强的 CAR T 促进树突状细胞 (DC) 招募至肿瘤，增加 DC 对肿瘤抗原的摄取，并引发内源性抗肿瘤 T 细胞的启动。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 6 月 28 日：S0092-8674(23)00642-6. doi: 10.1016/j.cell.2023.06.002. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">嵌合抗原受体（CAR）T细胞疗法可以有效治疗人类癌症，但CAR识别的抗原的丢失构成了主要障碍。我们发现体内CAR T细胞疫苗加强会触发内源性免疫系统的参与来规避抗原阴性肿瘤逃逸。疫苗增强的 CAR T 促进树突状细胞 (DC) 募集到肿瘤，增加 DC 对肿瘤抗原的摄取，并引发内源性抗肿瘤 T 细胞的氧化磷酸化 (OXPHOS)，并且严重依赖CAR-T 衍生的 IFN-γ。疫苗增强的 CAR T 诱导的抗原扩散（AS）即使在初始肿瘤 50% CAR 抗原阴性的情况下也能实现一定比例的完全缓解，并且遗传基因进一步增强了异质性肿瘤控制CAR T IFN-γ 表达的扩增。针对实体瘤的反应。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37413990/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37413990</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.06.002>10.1016/j.cell.2023.06.002</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37413990</guid><pubDate> Thu, 06 Jul 2023 06:00:00 -0400</pubDate><dc:creator>马乐源</dc:creator><dc:creator>亚历山大·霍斯特勒</dc:creator><dc:creator>邓肯·M·摩根</dc:creator><dc:creator>劳拉·马奥里诺</dc:creator><dc:creator>伊娜·苏尔卡杰</dc:creator><dc:creator>查尔斯·惠特克</dc:creator><dc:creator>亚历山德拉·尼瑟</dc:creator><dc:creator>伊万·苏辛·皮雷斯</dc:creator><dc:creator>帕里莎·优素福</dc:creator><dc:creator>——贾斯汀·格雷戈里</dc:creator><dc:creator>卡希夫·库雷希</dc:creator><dc:creator>乔纳森·戴伊</dc:creator><dc:creator>伍贝特·亚伯拉罕</dc:creator><dc:creator>徐熙京</dc:creator><dc:creator>李娜</dc:creator><dc:creator>J·克里斯托弗·洛夫</dc:creator><dc:creator>——达雷尔·J·欧文</dc:creator><dc:date>2023-07-06</dc:date><dc:source>细胞</dc:source><dc:title>疫苗增强的 CAR T 与宿主免疫串扰，以排斥具有抗原异质性的肿瘤</dc:title><dc:identifier>下午：37413990</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.002</dc:identifier></item><item><title>人类胚胎实时成像揭示囊胚扩张和活检过程中核 DNA 脱落</title><link/>https://pubmed.ncbi.nlm.nih.gov/37413989/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230710063622&amp;v=2.17.9.post6+86293ac<description>适当的植入前发育对于组装能够植入的囊胚至关重要。实时成像已经揭示了驱动小鼠胚胎早期发育的主要事件；然而，由于基因操作的限制和缺乏成像方法，人类研究受到限制。实时成像揭示人类染色体分离、压缩、极化、囊胚形成和孵化的动态... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 6 月 28 日：S0092-8674(23)00643-8. doi: 10.1016/j.cell.2023.06.003. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">适当的植入前发育对于组装能够植入的囊胚至关重要。实时成像已经揭示了驱动小鼠胚胎早期发育的主要事件；然而，由于基因操作的限制和缺乏成像方法，人类研究受到限制。实时成像揭示了人类胚胎中染色体分离、压缩、极化、囊胚形成和孵化的动态。我们还表明，囊胚扩张机械地限制滋养外胚层细胞，导致核出芽和 DNA 脱落到细胞质中。此外，具有较低水平的细胞核周角蛋白水平更容易发生 DNA 丢失。此外，应用滋养外胚层活检（一种临床上用于基因检测的机械程序）会增加 DNA 脱落。人类胚胎中的非整倍体可能不仅源于有丝分裂期间的染色体分离错误，还源于核 DNA脱落。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37413989/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37413989</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.06.003>10.1016/j.cell.2023.06.003</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37413989</guid><pubDate> Thu, 06 Jul 2023 06:00:00 -0400</pubDate><dc:creator>安娜·多明戈·穆拉斯</dc:creator><dc:creator>罗宾·M·斯科里</dc:creator><dc:creator>亚当·莫弗利</dc:creator><dc:creator>戈利阿德斯塔尼</dc:creator><dc:creator>奥兹盛况</dc:creator><dc:creator>卡门·卢比奥</dc:creator><dc:creator>彼得·泰特拉克</dc:creator><dc:creator>布莱克·埃尔南德斯</dc:creator><dc:creator>埃里克·A·罗恩-卡尔德隆</dc:creator><dc:creator>路易斯·纳瓦罗-桑切斯</dc:creator><dc:creator>卡门·M·加西亚-帕斯夸尔</dc:creator><dc:creator>斯蒂芬妮·比西埃</dc:creator><dc:creator>玛丽莎·巴托洛梅</dc:creator><dc:creator>丹尼·萨卡斯</dc:creator><dc:creator>卡洛斯·西蒙</dc:creator><dc:creator>尼古拉斯·普拉赫塔</dc:creator><dc:date>2023-07-06</dc:date><dc:source>细胞</dc:source><dc:title>人类胚胎实时成像揭示囊胚扩张和活检过程中核 DNA 脱落</dc:title><dc:identifier>下午：37413989</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.003</dc:identifier></item><item><title>值得关注的 SARS-CoV-2 变种在全球扩张期间的传播模式和航空旅行的影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/37413988/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230710063622&amp;v=2.17.9.post6+86293ac<description> SARS-CoV-2 的 Alpha、Beta 和 Gamma SARS-CoV-2 变种 (VOC) 在 2020 年和 2021 年期间在全球范围内共同传播，加剧了感染浪潮。在 2021 年全球第三波感染浪潮中，它们被 Delta 病毒取代，这反过来又导致于 2021 年底被 Omicron 取代。在这项研究中，我们使用系统发育和系统发育地理学方法来重建全球 VOC 的扩散模式。我们发现源-库动态因 VOC 的不同而有很大差异，并确定了充当全球和区域性角色的国家…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 6 月 7 日：S0092-8674(23)00641-4.doi: 10.1016/j.cell.2023.06.001.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> SARS-CoV-2 的 Alpha、Beta 和 Gamma SARS-CoV-2 变种 (VOC) 在 2020 年和 2021 年期间在全球范围内共同传播，加剧了感染浪潮。在 2021 年全球第三波感染浪潮中，它们被 Delta 病毒取代，这反过来又导致于 2021 年底被 Omicron 取代。在这项研究中，我们使用系统发育和系统发育地理学方法来重建全球 VOC 的扩散模式。我们发现源-汇动态因 VOC 的不同而有很大差异，并确定了充当全球和区域传播中心的国家我们证明了 VOC 的假定原产国在其全球扩散中的作用正在下降，估计印度贡献了 Delta 出口的 &lt;15%，南非则贡献了 Omicron 扩散的 &lt;1%-2%。Omicron 在其出现后 100 天内，与加速相关乘客航空旅行和更高的传染性。我们的研究强调了高传染性变种的快速传播，这对分级航空公司网络上的基因组监测具有影响。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37413988/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37413988</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10247138/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">PMC10247138</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.06.001>10.1016/j.cell.2023.06.001</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37413988</guid><pubDate> Thu, 06 Jul 2023 06:00:00 -0400</pubDate><dc:creator>胡里耶·泰加利</dc:creator><dc:creator>埃杜安·威尔金森</dc:creator><dc:creator>徐立恒</dc:creator><dc:creator>莫妮卡莫伊尔</dc:creator><dc:creator>达伦·马丁</dc:creator><dc:creator>安德森·费尔南德斯·布里托</dc:creator><dc:creator>玛尔塔·乔瓦内蒂</dc:creator><dc:creator>卡姆兰·汗</dc:creator><dc:creator>卡门胡贝尔</dc:creator><dc:creator>艾萨克·博戈赫</dc:creator><dc:creator>詹姆斯·伊曼纽尔·桑</dc:creator><dc:creator>杰妮卡·庞加南</dc:creator><dc:creator>乔西马拉·S·泽维尔</dc:creator><dc:creator>达尔兰·达·S·坎迪多</dc:creator><dc:creator>菲利普·罗梅罗</dc:creator><dc:creator>谢丽尔·巴克斯特</dc:creator><dc:creator>奥利弗·G·皮布斯</dc:creator><dc:creator>——理查德·J·莱塞尔斯</dc:creator><dc:creator>努诺·R·法利亚</dc:creator><dc:creator>莫里茨·UG·克雷默</dc:creator><dc:creator>图利奥·德·奥利维拉</dc:creator><dc:date>2023-07-06</dc:date><dc:source>细胞</dc:source><dc:title>值得关注的 SARS-CoV-2 变种在全球扩张期间的传播模式和航空旅行的影响</dc:title><dc:identifier>下午：37413988</dc:identifier><dc:identifier>管理中心：PMC10247138</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.001</dc:identifier></item><item><title>功能性病毒组筛选揭示调控 RNA 元件</title><link/>https://pubmed.ncbi.nlm.nih.gov/37413987/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230710063622&amp;v=2.17.9.post6+86293ac<description>最近，已测序的病毒基因组数量激增，为了解病毒多样性和揭示未知的调控机制提供了机会。在这里，我们对来自代表 96 个属和 37 个科的 143 个物种的 30,367 个病毒片段进行了筛选。3&#39; UTR，我们鉴定了数百个病毒片段影响 RNA 丰度、翻译和核质分布的元素。为了说明这种方法的威力，我们研究了 K5，一种元素…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 6 月 28 日：S0092-8674(23)00675-X. doi: 10.1016/j.cell.2023.06.007. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">最近，已测序的病毒基因组数量激增，为了解病毒多样性和揭示未知的调控机制提供了机会。在这里，我们对来自代表 96 个属和 37 个科的 143 个物种的 30,367 个病毒片段进行了筛选。3&#39; UTR，我们鉴定了数百个病毒片段影响RNA丰度、翻译和核质分布的元素。为了说明这种方法的威力，我们研究了K5，一种在kobuviruses中保守的元素，并发现其在各种情况下增强mRNA稳定性和翻译的强大能力此外，我们还发现了一种以前未表征的元素蛋白质 ZCCHC2 是 K5 的关键宿主因子。ZCCHC2 招募末端核苷酸转移酶 TENT4 来延长具有混合序列的聚 (A) 尾，延迟去腺苷化。这项研究为病毒和 RNA 研究提供了独特的资源，并强调了该研究的潜力用于生物学发现的病毒圈。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37413987/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37413987</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.06.007>10.1016/j.cell.2023.06.007</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37413987</guid><pubDate> Thu, 06 Jul 2023 06:00:00 -0400</pubDate><dc:creator>珍妮·J·徐</dc:creator><dc:creator>郑秀珍</dc:creator><dc:creator>杨智惠</dc:creator><dc:creator>崔多恩</dc:creator><dc:creator>V纳里·金</dc:creator><dc:date>2023-07-06</dc:date><dc:source>细胞</dc:source><dc:title>功能性病毒组筛选揭示调控 RNA 元件</dc:title><dc:identifier>下午：37413987</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.007</dc:identifier></item><item><title>更正：使用计算生态系统分析肾心串扰</title><link/>https://pubmed.ncbi.nlm.nih.gov/37410859/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230710063622&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023年7月7日；133(2):e47.doi: 10.1161/RES.0000000000000619.Epub 2023年7月6日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37410859/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37410859</a> | DOI： <a href=https://doi.org/10.1161/RES.0000000000000619>10.1161/RES.0000000000000619</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37410859</guid><pubDate> Thu, 06 Jul 2023 06:00:00 -0400</pubDate><dc:date> 2023-07-06</dc:date><dc:source>流通研究</dc:source><dc:title>更正：使用计算生态系统分析肾心串扰</dc:title><dc:identifier>下午：37410859</dc:identifier><dc:identifier> doi:10.1161/RES.0000000000000619</dc:identifier></item><item><title>认识第一作者</title><link/>https://pubmed.ncbi.nlm.nih.gov/37410857/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230710063622&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 7 月 7 日；133(2):106-107。doi: 10.1161/RES.0000000000000621。Epub 2023 年 7 月 6 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37410857/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37410857</a> | DOI： <a href=https://doi.org/10.1161/RES.0000000000000621>10.1161/RES.0000000000000621</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37410857</guid><pubDate> Thu, 06 Jul 2023 06:00:00 -0400</pubDate><dc:date> 2023-07-06</dc:date><dc:source>流通研究</dc:source><dc:title>认识第一作者</dc:title><dc:identifier>下午：37410857</dc:identifier><dc:identifier> doi:10.1161/RES.0000000000000621</dc:identifier></item><item><title>恶性双胞胎：RyR2 功能障碍和结构重塑</title><link/>https://pubmed.ncbi.nlm.nih.gov/37410856/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230710063622&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 7 月 7 日；133(2):193-195。doi: 10.1161/CIRCRESAHA.123.323144。Epub 2023 年 7 月 6 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37410856/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37410856</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323144>10.1161/CIRCRESAHA.123.323144</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37410856</guid><pubDate> Thu, 06 Jul 2023 06:00:00 -0400</pubDate><dc:creator>尼尔斯·沃伊特</dc:creator><dc:creator>菲茨威廉·塞伯特</dc:creator><dc:creator>丰绍·法库阿德</dc:creator><dc:date>2023-07-06</dc:date><dc:source>流通研究</dc:source><dc:title>恶性双胞胎：RyR2 功能障碍和结构重塑</dc:title><dc:identifier>下午：37410856</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323144</dc:identifier></item><item><title>细胞外囊泡封装的 AAV 用于将治疗性基因递送至心脏</title><link/>https://pubmed.ncbi.nlm.nih.gov/37409482/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230710063622&amp;v=2.17.9.post6+86293ac<description>结论：通过使用 5 种不同的体外和体内模型系统，我们证明在 NAbs 基因递送工具存在的情况下，EV-AAV 载体与游离 AAV 相比具有显着更高的效力和治疗效果。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 7 月 6 日。doi：10.1161/CIRCULATIONAHA.122.063759。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：腺相关病毒（AAV）因其亲心性、长期表达和安全性而成为心脏基因传递的最佳工具之一。），它与游离的 AAV 结合，阻止有效的基因转导，并减少或减少基因转导。否定治疗效果，传递更多基因并提供更高的 Nab 抗性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们开发了一种两步密度梯度超速离心方法来分离高度纯化的 EV-AAV。我们在 NAb 存在的情况下，在体外和体外比较了 EV-AAV 与等滴度游离 AAV 的基因递送和治疗效果。此外，我们结合生化技术、流式细胞术和免疫荧光成像研究了体外人左心室和人诱导多能干细胞心肌细胞以及体内小鼠模型中 EV-AAV 摄取的机制。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Using cardiotropic AAV serotypes 6 and 9 and several reporter constructs, we demonstrated that EV-AAVs deliver significantly higher quantities of genes than AAVs in the presence of NAbs, both to human left ventricular and human induced pluripotent stem cell cardiomyocytes in vitro and to mouse hearts in vivo. Intramyocardial delivery of EV-AAV9- sarcoplasmic reticulum calcium ATPase 2a to infarcted hearts in preimmunized mice significantly improved ejection fraction and fractional shortening compared with AAV9-sarcoplasmic reticulum calcium ATPase 2a delivery. These data validated NAb evasion by and therapeutic efficacy of EV-AAV9 vectors. Trafficking studies using human induced pluripotent stem cell-derived cells in vitro and mouse hearts in vivo showed significantly higher expression of EV-AAV6/9-delivered genes in cardiomyocytes compared with noncardiomyocytes, even with comparable cellular uptake. Using cellular subfraction analyses and pH-sensitive dyes, we discovered that EV-AAVs were internalized into acidic endosomal compartments of cardiomyocytes for releasing and acidifying AAVs for their nuclear uptake. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Together, using 5 different in vitro and in vivo model systems, we demonstrate significantly higher potency and therapeutic efficacy of EV-AAV vectors compared with free AAVs in the presence of NAbs. These results establish the potential of EV-AAV vectors as a gene delivery tool to treat heart failure.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37409482/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37409482</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063759>10.1161/CIRCULATIONAHA.122.063759</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37409482</guid><pubDate> Thu, 06 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Xisheng Li</dc:creator><dc:creator> Sabrina La Salvia</dc:creator><dc:creator> Yaxuan Liang</dc:creator><dc:creator> Marta Adamiak</dc:creator><dc:creator> Erik Kohlbrenner</dc:creator><dc:creator> Dongtak Jeong</dc:creator><dc:creator> Elena Chepurko</dc:creator><dc:creator> Delaine Ceholski</dc:creator><dc:creator> Estrella Lopez-Gordo</dc:creator><dc:creator> Seonghun Yoon</dc:creator><dc:creator> Prabhu Mathiyalagan</dc:creator><dc:creator> Neha Agarwal</dc:creator><dc:creator> Divya Jha</dc:creator><dc:creator> Shweta Lodha</dc:creator><dc:creator> George Daaboul</dc:creator><dc:creator> Anh Phan</dc:creator><dc:creator> Nikhil Raisinghani</dc:creator><dc:creator> Shihong Zhang</dc:creator><dc:creator> Lior Zangi</dc:creator><dc:creator> Edgar Gonzalez Kozlova</dc:creator><dc:creator> Nicole Dubois</dc:creator><dc:creator> Navneet Dogra</dc:creator><dc:creator> Roger J Hajjar</dc:creator><dc:creator> Susmita Sahoo</dc:creator><dc:date> 2023-07-06</dc:date><dc:source> Circulation</dc:source><dc:title> Extracellular Vesicle-Encapsulated AAVs for Therapeutic Gene Delivery to the Heart</dc:title><dc:identifier> pmid:37409482</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.122.063759</dc:identifier></item><item><title> P53 Regulates the Extent of Fibroblast Proliferation and Fibrosis in Left Ventricle Pressure Overload</title><link/> https://pubmed.ncbi.nlm.nih.gov/37409456/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230710063622&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: This study reveals a mechanism regulating cardiac fibroblast accumulation and ECM secretion, orchestrated in part by p53-dependent cell cycle control that governs the timing and extent of fibrosis in left ventricular pressure overload. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Jul 6. doi: 10.1161/CIRCRESAHA.121.320324. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Cardiomyopathy is characterized by the pathological accumulation of resident cardiac fibroblasts that deposit ECM (extracellular matrix) and generate a fibrotic scar. However, the mechanisms that control the timing and extent of cardiac fibroblast proliferation and ECM production are not known, hampering the development of antifibrotic strategies to prevent heart failure. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We used the Tcf21 (transcription factor 21) <sup>MerCreMer</sup> mouse line for fibroblast-specific lineage tracing and tumor protein p53 ( <i>p53</i> ) gene deletion (called p53-cardiac fibroblasts knockout). We characterized cardiac physiology and used single-cell RNA-sequencing and in vitro studies to investigate the p53-dependent mechanisms regulating cardiac fibroblast cell cycle and fibrosis in left ventricular pressure overload induced by transaortic constriction. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Cardiac fibroblast proliferation occurs primarily between days 7 and 14 following transaortic constriction in mice, correlating with alterations in p53-dependent gene expression. P53 deletion in fibroblasts led to a striking accumulation of Tcf21-lineage cardiac fibroblasts within the normal proliferative window and precipitated a robust fibrotic response to left ventricular pressure overload. However, excessive interstitial and perivascular fibrosis does not develop in p53-cardiac fibroblasts knockout mice until after cardiac fibroblasts exit the cell cycle. Single-cell RNA sequencing revealed p53 null fibroblasts unexpectedly express lower levels of genes encoding important ECM proteins while they exhibit an inappropriately proliferative phenotype. in vitro studies establish a role for p53 in suppressing the proliferative fibroblast phenotype, which facilitates the expression and secretion of ECM proteins. Importantly, <i>Cdkn2a</i> expression and the p16 <sup>Ink4a</sup> -retinoblastoma cell cycle control pathway is induced in <i>p53</i> null cardiac fibroblasts, which may eventually contribute to cell cycle exit and fulminant scar formation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: This study reveals a mechanism regulating cardiac fibroblast accumulation and ECM secretion, orchestrated in part by p53-dependent cell cycle control that governs the timing and extent of fibrosis in left ventricular pressure overload.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37409456/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37409456</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.121.320324>10.1161/CIRCRESAHA.121.320324</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37409456</guid><pubDate> Thu, 06 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Xiaoyi Liu</dc:creator><dc:creator> Ryan M Burke</dc:creator><dc:creator> Janet K Lighthouse</dc:creator><dc:creator> Cameron D Baker</dc:creator><dc:creator> Ronald A Dirkx</dc:creator><dc:creator> Brian Kang</dc:creator><dc:creator> Yashoswini Chakraborty</dc:creator><dc:creator> Deanne M Mickelsen</dc:creator><dc:creator> Jennifer Twardowski</dc:creator><dc:creator> Stephano S Mello</dc:creator><dc:creator> John M Ashton</dc:creator><dc:creator> Eric M Small</dc:creator><dc:date> 2023-07-06</dc:date><dc:source> Circulation research</dc:source><dc:title> P53 Regulates the Extent of Fibroblast Proliferation and Fibrosis in Left Ventricle Pressure Overload</dc:title><dc:identifier> pmid:37409456</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.121.320324</dc:identifier></item><item><title> Sudden cardiac arrest in adult congenital heart disease: a challenge to be tackled</title><link/> https://pubmed.ncbi.nlm.nih.gov/37409418/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230710063622&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 6:ehad416. doi: 10.1093/eurheartj/ehad416. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37409418/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37409418</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad416>10.1093/eurheartj/ehad416</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37409418</guid><pubDate> Thu, 06 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Victor Waldmann</dc:creator><dc:creator> Kumar Narayanan</dc:creator><dc:creator> Eloi Marijon</dc:creator><dc:date> 2023-07-06</dc:date><dc:source> European heart journal</dc:source><dc:title> Sudden cardiac arrest in adult congenital heart disease: a challenge to be tackled</dc:title><dc:identifier> pmid:37409418</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad416</dc:identifier></item><item><title> Outcomes of out-of-hospital cardiac arrest in adult congenital heart disease: a Danish nationwide study</title><link/> https://pubmed.ncbi.nlm.nih.gov/37409410/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230710063622&amp;v=2.17.9.post6+86293ac<description> CONCLUSION: A higher risk of OHCA was found throughout the spectrum of CHD. Patients with and without CHD showed the same 30-day survival, which relies on the pre-hospital chain of survival, namely cardiopulmonary resuscitation and defibrillation. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 6:ehad358. doi: 10.1093/eurheartj/ehad358. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> AIMS: The risk, characteristics, and outcome of out-of-hospital cardiac arrest (OHCA) in patients with congenital heart disease (CHD) remain scarcely investigated. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS AND RESULTS: An epidemiological registry-based study was conducted. Using time-dependent Cox regression models fitted with a nested case-control design, hazard ratios (HRs) with 95% confidence intervals of OHCA of presumed cardiac cause (2001-19) associated with simple, moderate, and severe CHD were calculated. Moreover, using multiple logistic regression, we investigated the association between pre-hospital OHCA characteristics and 30-day survival and compared 30-day survival in OHCA patients with and without CHD. Overall, 43 967 cases (105 with simple, 144 with moderate, and 53 with severe CHD) and 219 772 controls (median age 72 years, 68.2% male) were identified. Any type of CHD was found to be associated with higher rates of OHCA compared with the background population [simple CHD: HR 1.37 (1.08-1.70); moderate CHD: HR 1.64 (1.36-1.99); and severe CHD: HR 4.36 (3.01-6.30)]. Pre-hospital cardiopulmonary resuscitation and defibrillation were both associated with improved 30-day survival in patients with CHD, regardless of CHD severity. Among patients with OHCA, simple, moderate, and severe CHD had a similar likelihood of 30-day survival compared with no CHD [odds ratio 0.95 (0.53-1.69), 0.70 (0.43-1.14), and 0.68 (0.33-1.57), respectively]. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: A higher risk of OHCA was found throughout the spectrum of CHD. Patients with and without CHD showed the same 30-day survival, which relies on the pre-hospital chain of survival, namely cardiopulmonary resuscitation and defibrillation.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37409410/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37409410</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad358>10.1093/eurheartj/ehad358</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37409410</guid><pubDate> Thu, 06 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Carlo Alberto Barcella</dc:creator><dc:creator> Daniel Mølager Christensen</dc:creator><dc:creator> Lars Idorn</dc:creator><dc:creator> Nishan Mudalige</dc:creator><dc:creator> Morten Malmborg</dc:creator><dc:creator> Frederik Folke</dc:creator><dc:creator> Christian Torp-Pedersen</dc:creator><dc:creator> Gunnar Gislason</dc:creator><dc:creator> Mohamad El-Chouli</dc:creator><dc:date> 2023-07-06</dc:date><dc:source> European heart journal</dc:source><dc:title> Outcomes of out-of-hospital cardiac arrest in adult congenital heart disease: a Danish nationwide study</dc:title><dc:identifier> pmid:37409410</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad358</dc:identifier></item><item><title> The CODE-EHR global framework: lifting the veil on health record data</title><link/> https://pubmed.ncbi.nlm.nih.gov/37408471/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230710063622&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 6:ehad424. doi: 10.1093/eurheartj/ehad424. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37408471/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37408471</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad424>10.1093/eurheartj/ehad424</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37408471</guid><pubDate> Thu, 06 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Folkert W Asselbergs</dc:creator><dc:creator> Dipak Kotecha</dc:creator><dc:date> 2023-07-06</dc:date><dc:source> European heart journal</dc:source><dc:title> The CODE-EHR global framework: lifting the veil on health record data</dc:title><dc:identifier> pmid:37408471</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad424</dc:identifier></item><item><title> P2Y&lt;sub>;12&lt;/sub>; Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events</title><link/> https://pubmed.ncbi.nlm.nih.gov/37407118/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230710063622&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Given its superior efficacy and similar overall safety, P2Y(12) inhibitor monotherapy might be preferred over aspirin monotherapy for long-term secondary prevention in patients with established CAD. (P2Y(12) Inhibitor or Aspirin Monotherapy as Secondary Prevention in Patients With Coronary Artery Disease: An Individual Patient Data Meta-Analysis of Randomized Trials [PANTHER collaborative initiative]; CRD42021290774). </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Jul 11;82(2):89-105. doi: 10.1016/j.jacc.2023.04.051.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Aspirin is the only antiplatelet agent with a Class I recommendation for long-term prevention of cardiovascular events in patients with coronary artery disease (CAD). There is inconsistent evidence on how it compares with alternative antiplatelet agents. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: This study compared P2Y <sub>12</sub> inhibitor monotherapy vs aspirin in patients with CAD. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We conducted a patient-level meta-analysis of randomized trials comparing P2Y <sub>12</sub> inhibitor monotherapy vs aspirin monotherapy for the prevention of cardiovascular events in patients with established CAD. The primary outcome was the composite of cardiovascular death, myocardial infarction, and stroke. Prespecified key secondary outcomes were major bleeding and net adverse clinical events (the composite of the primary outcome and major bleeding). Data were pooled in a 1-step meta-analysis. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Patient-level data were obtained from 7 trials. Overall, 24,325 participants were available for analysis, including 12,178 patients assigned to receive P2Y <sub>12</sub> inhibitor monotherapy (clopidogrel in 7,545 [62.0%], ticagrelor in 4,633 [38.0%]) and 12,147 assigned to receive aspirin. Risk of the primary outcome was lower with P2Y <sub>12</sub> inhibitor monotherapy compared with aspirin over 2 years (HR: 0.88; 95% CI: 0.79-0.97; P = 0.012), mainly owing to less myocardial infarction (HR: 0.77; 95% CI: 0.66-0.90; P &lt; 0.001). Major bleeding was similar (HR: 0.87; 95% CI: 0.70-1.09; P = 0.23) and net adverse clinical events were lower (HR: 0.89; 95% CI: 0.81-0.98; P = 0.020) with P2Y <sub>12</sub> inhibitors. The treatment effect was consistent across prespecified subgroups and types of P2Y <sub>12</sub> inhibitors. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Given its superior efficacy and similar overall safety, P2Y <sub>12</sub> inhibitor monotherapy might be preferred over aspirin monotherapy for long-term secondary prevention in patients with established CAD. (P2Y <sub>12</sub> Inhibitor or Aspirin Monotherapy as Secondary Prevention in Patients With Coronary Artery Disease: An Individual Patient Data Meta-Analysis of Randomized Trials [PANTHER collaborative initiative]; CRD42021290774).</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37407118/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230710063622&v=2.17.9.post6+86293ac">37407118</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.04.051>10.1016/j.jacc.2023.04.051</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37407118</guid><pubDate> Wed, 05 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Felice Gragnano</dc:creator><dc:creator> Davide Cao</dc:creator><dc:creator> Leah Pirondini</dc:creator><dc:creator> Anna Franzone</dc:creator><dc:creator> Hyo-Soo Kim</dc:creator><dc:creator> Moritz von Scheidt</dc:creator><dc:creator> Alf-Åge R Pettersen</dc:creator><dc:creator> Qiang Zhao</dc:creator><dc:creator> Mark Woodward</dc:creator><dc:creator> Mauro Chiarito</dc:creator><dc:creator> Eugene P McFadden</dc:creator><dc:creator> Kyung Woo Park</dc:creator><dc:creator> Adnan Kastrati</dc:creator><dc:creator> Ingebjørg Seljeflot</dc:creator><dc:creator> Yunpeng Zhu</dc:creator><dc:creator> Stephan Windecker</dc:creator><dc:creator> Jeehoon Kang</dc:creator><dc:creator> Heribert Schunkert</dc:creator><dc:creator> Harald Arnesen</dc:creator><dc:creator> Deepak L Bhatt</dc:creator><dc:creator> Philippe Gabriel Steg</dc:creator><dc:creator> Paolo Calabrò</dc:creator><dc:creator> Stuart Pocock</dc:creator><dc:creator> Roxana Mehran</dc:creator><dc:creator> Marco Valgimigli</dc:creator><dc:creator> PANTHER Collaboration</dc:creator><dc:date> 2023-07-05</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> P2Y&lt;sub>;12&lt;/sub>; Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events</dc:title><dc:identifier> pmid:37407118</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.04.051</dc:identifier></item></channel></rss>